Russell Investments Group Ltd. Increases Stock Position in Stryker Corporation $SYK

Key Points

• Russell Investments increased its Stryker position by 54.2% in the second quarter, adding 147,977 shares to hold 420,962 shares worth approximately $133.6 million. Institutional investors collectively own 77.09% of Stryker.
• Stryker reported quarterly EPS of $3.69, exceeding estimates of $3.49, while revenue rose 9.4% year over year to $6.59 billion. The company maintained fiscal 2026 EPS guidance of $14.95–$15.10.
• Analysts retain a generally positive view, with a consensus “Moderate Buy” rating and a $386.28 price target, although several firms recently lowered targets. Stryker also declared a quarterly dividend of $0.88 per share, yielding about 1.0% annually.

Russell Investments Group Ltd. grew its holdings in shares of Stryker Corporation (NYSE:SYK - Free Report) by 54.2% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 420,962 shares of the medical technology company's stock after buying an additional 147,977 shares during the period. Russell Investments Group Ltd. owned 0.11% of Stryker worth $133,576,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the business. Godfrey Financial Associates Inc. bought a new position in shares of Stryker in the 4th quarter worth about $26,000. Sankala Group LLC bought a new stake in Stryker during the fourth quarter worth about $26,000. United Financial Planning Group LLC bought a new stake in Stryker during the third quarter worth about $27,000. Atlas Capital Advisors Inc. purchased a new stake in Stryker in the fourth quarter worth about $27,000. Finally, DJE Kapital AG purchased a new stake in Stryker in the fourth quarter worth about $28,000. 77.09% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Stryker

In other news, VP Robert S. Fletcher sold 4,544 shares of the business's stock in a transaction on Thursday, May 28th. The stock was sold at an average price of $306.87, for a total value of $1,394,417.28. Following the completion of the transaction, the vice president owned 10,582 shares in the company, valued at $3,247,298.34. The trade was a 30.04% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Ronda E. Stryker sold 310,000 shares of the company's stock in a transaction on Tuesday, May 26th. The shares were sold at an average price of $312.23, for a total value of $96,791,300.00. Following the transaction, the director directly owned 1,924,880 shares in the company, valued at approximately $601,005,282.40. The trade was a 13.87% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Corporate insiders own 4.60% of the company's stock.

Analyst Upgrades and Downgrades

SYK has been the subject of a number of analyst reports. BTIG Research decreased their target price on shares of Stryker from $371.00 to $358.00 and set a "buy" rating for the company in a research note on Friday, July 31st. Wells Fargo & Company cut their price target on Stryker from $456.00 to $418.00 and set an "overweight" rating on the stock in a research note on Friday, May 1st. BMO Capital Markets initiated coverage on Stryker in a research note on Wednesday, July 8th. They issued an "outperform" rating and a $369.00 price target on the stock. JPMorgan Chase & Co. reduced their price objective on Stryker from $400.00 to $350.00 and set an "overweight" rating for the company in a research report on Friday, July 31st. Finally, Wolfe Research cut Stryker from an "outperform" rating to a "peer perform" rating in a research note on Thursday. One analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and six have given a Hold rating to the company. According to MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $386.28.

Stryker Stock Down 0.1%

Shares of Stryker stock opened at $338.80 on Monday. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.33 and a current ratio of 2.16. The stock has a market capitalization of $129.95 billion, a PE ratio of 35.11, a price-to-earnings-growth ratio of 2.16 and a beta of 0.76. Stryker Corporation has a 52-week low of $281.00 and a 52-week high of $396.86. The company has a 50-day simple moving average of $324.61 and a two-hundred day simple moving average of $333.40.

Stryker (NYSE:SYK - Get Free Report) last issued its earnings results on Thursday, July 30th. The medical technology company reported $3.69 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.49 by $0.20. Stryker had a net margin of 14.43% and a return on equity of 23.63%. The firm had revenue of $6.59 billion for the quarter, compared to the consensus estimate of $6.58 billion. During the same quarter in the prior year, the firm posted $3.13 earnings per share. The business's revenue was up 9.4% on a year-over-year basis. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. On average, analysts anticipate that Stryker Corporation will post 15.02 EPS for the current fiscal year.

Stryker Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, October 30th. Investors of record on Wednesday, September 30th will be given a $0.88 dividend. The ex-dividend date of this dividend is Wednesday, September 30th. This represents a $3.52 annualized dividend and a yield of 1.0%. Stryker's dividend payout ratio is 36.48%.

Stryker Company Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons' offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source